Page last updated: 2024-08-24

ziprasidone and perphenazine

ziprasidone has been researched along with perphenazine in 31 studies

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's19 (61.29)29.6817
2010's11 (35.48)24.3611
2020's1 (3.23)2.80

Authors

AuthorsStudies
Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S1
Herrick-Davis, K; Purohit, A; Smith, C; Teitler, M1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Lieberman, JA; Stroup, TS1
Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lebowitz, BD; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS1
Luchins, DJ1
Hsiao, JK; Lieberman, JA1
Banks, SM; Pandiani, JA1
Anghelescu, IG; Dettling, M1
Capuano, G; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; McGee, MF; Perkins, DO; Reimherr, F; Rosenheck, RA; Stroup, TS; Swartz, MS1
Bilder, RM; Capuano, G; Davis, CE; Davis, SM; Gold, JM; Green, MF; Harvey, PD; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Palmer, BW; Perkins, DO; Rosenheck, RA; Stroup, TS; Swartz, MS1
Bick, P; Castle, D; Knoesen, N1
Allingham, B; Citrome, L; Jaffe, A; Levine, J; Martello, D1
Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Rosenheck, RA; Stroup, TS; Swartz, MS1
Daumit, GL; Davis, SM; Davis, VG; Goff, DC; Hsiao, J; Lieberman, JA; McEvoy, JP; Meyer, JM; Nasrallah, HA; Stroup, TS; Swartz, MS1
Fusar-Poli, RR1
Ayesa, R; Crespo-Facorro, B; Martínez-Garcia, O; Mata, I; Pérez-Iglesias, R; Ramirez-Bonilla, M; Rodríguez-Sánchez, JM; Vázquez-Barquero, JL1
Aberg, K; Adkins, DE; Lieberman, JA; McClay, JL; Perkins, DO; Stroup, S; Sullivan, PF; van den Oord, EJ; Vladimirov, VI1
Campbell, EC; Caroff, SN; Chakos, MH; Davis, SM; Davis, VG; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, DD; Riggio, S; Rosenheck, RA; Saltz, BL; Stroup, TS; Swartz, MS1
Dudova, I; Hrdlicka, M; Urbanek, T; Zedkova, I1
Arnold, JG; Cañive, JM; Miller, AL; Mintz, J; Rosenheck, RA; Swartz, MS1
Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J1
Lin, H; Rosenheck, R1
Brennan, MD; Ramsey, TL1
Lin, H; McEvoy, J; Mohamed, S; Rosenheck, RA; Stroup, S; Swartz, M1
Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T1
Bellavia, A; Centorrino, F; Fitzmaurice, G; Jackson, JW; Valeri, L1
Correll, CU; DiPetrillo, L; Jiang, Y; Liu, Y; Pathak, S; Todtenkopf, MS1

Reviews

2 review(s) available for ziprasidone and perphenazine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
    The Cochrane database of systematic reviews, 2018, Jan-22, Volume: 1

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disorders; Olanzapine; Patient Dropouts; Perphenazine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Substance-Related Disorders; Thiazoles

2018

Trials

15 trial(s) available for ziprasidone and perphenazine

ArticleYear
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Method; Female; Humans; Lipids; Male; Olanzapine; Patient Compliance; Perphenazine; Piperazines; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain

2005
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
    The American journal of psychiatry, 2007, Volume: 164, Issue:3

    Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Follow-Up Studies; Health Status; Humans; National Institute of Mental Health (U.S.); Olanzapine; Patient Dropouts; Perphenazine; Piperazines; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Adjustment; Thiazoles; Treatment Outcome; United States

2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Archives of general psychiatry, 2007, Volume: 64, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Cohort Studies; Dibenzothiazepines; Double-Blind Method; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome

2007
Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.
    Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2007, Volume: 15, Issue:6

    Topics: Antipsychotic Agents; Australia; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; Humans; Olanzapine; Perphenazine; Piperazines; Psychiatry; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Time Factors

2007
What CATIE found: results from the schizophrenia trial.
    Psychiatric services (Washington, D.C.), 2008, Volume: 59, Issue:5

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Psychology; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles

2008
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
    Schizophrenia research, 2008, Volume: 103, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cardiovascular Diseases; Dibenzothiazepines; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risk Factors; Risperidone; Schizophrenia; Thiazoles; Triglycerides

2008
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
    The Journal of clinical psychiatry, 2009, Apr-21, Volume: 70, Issue:5

    Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Female; Follow-Up Studies; Haloperidol; Humans; Male; Neuropsychological Tests; Olanzapine; Perphenazine; Piperazines; Prospective Studies; Psychotic Disorders; Risperidone; Severity of Illness Index; Sulpiride; Thiazoles

2009
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.
    Molecular psychiatry, 2011, Volume: 16, Issue:1

    Topics: Antipsychotic Agents; Benzodiazepines; Chromosomes, Human, Pair 4; Dibenzothiazepines; Double-Blind Method; Follow-Up Studies; Genome-Wide Association Study; Humans; Olanzapine; Perphenazine; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome

2011
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Movement Disorders; Olanzapine; Perphenazine; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome

2011
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
    CNS spectrums, 2014, Volume: 19, Issue:5

    Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostility; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride; Thiazoles

2014
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
    The Journal of nervous and mental disease, 2014, Volume: 202, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Sample Size; Schizophrenia; Thiazoles; Treatment Outcome

2014
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
    Schizophrenia research, 2014, Volume: 160, Issue:1-3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Dibenzothiazepines; Female; Genotyping Techniques; Glucagon-Like Peptide-1 Receptor; Haplotypes; Humans; Male; Models, Genetic; Olanzapine; Perphenazine; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Receptors, Glucagon; Regression Analysis; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Weight Gain; White People

2014
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
    The Journal of nervous and mental disease, 2015, Volume: 203, Issue:7

    Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Cross-Sectional Studies; Dibenzothiazepines; Double-Blind Method; Female; Humans; Illicit Drugs; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Smoking; Smoking Prevention; Substance-Related Disorders; Thiazoles; Young Adult

2015
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.
    Schizophrenia research, 2019, Volume: 206

    Topics: Adult; Antipsychotic Agents; Body-Weight Trajectory; Female; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Weight Gain

2019
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
    The Journal of clinical psychiatry, 2020, 03-17, Volume: 81, Issue:2

    Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Hospitalization; Humans; Male; Olanzapine; Outcome Assessment, Health Care; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Symptom Flare Up; Thiazoles; Time Factors

2020

Other Studies

14 other study(ies) available for ziprasidone and perphenazine

ArticleYear
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:3

    Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain

2003
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
    Psychopharmacology, 2005, Volume: 179, Issue:2

    Topics: Amino Acid Substitution; Antipsychotic Agents; Cell Line; Cyclic AMP; Humans; Mutagenesis, Site-Directed; Mutation; Radioligand Assay; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Transfection

2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Schizophrenia, VI: Treatments.
    The American journal of psychiatry, 2003, Volume: 160, Issue:10

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Perphenazine; Piperazines; Pirenzepine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome

2003
Interpreting the results of the CATIE study.
    Psychiatric services (Washington, D.C.), 2006, Volume: 57, Issue:1

    Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; National Institute of Mental Health (U.S.); Perphenazine; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; United States

2006
Interpreting the results of the CATIE study.
    Psychiatric services (Washington, D.C.), 2006, Volume: 57, Issue:1

    Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome

2006
Interpreting the results of the CATIE study.
    Psychiatric services (Washington, D.C.), 2006, Volume: 57, Issue:1

    Topics: Antipsychotic Agents; Dibenzothiazepines; Humans; Perphenazine; Piperazines; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome

2006
Antipsychotic drugs and schizophrenia.
    The New England journal of medicine, 2006, Jan-19, Volume: 354, Issue:3

    Topics: Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Perphenazine; Piperazines; Quetiapine Fumarate; Schizophrenia; Thiazoles

2006
Did CATIE influence antipsychotic use?
    Psychiatric services (Washington, D.C.), 2008, Volume: 59, Issue:5

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Humans; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Thiazoles

2008
Clinical experiences and clinical trials.
    CNS spectrums, 2008, Volume: 13, Issue:6

    Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine; Perphenazine; Piperazines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome

2008
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
    Neuro endocrinology letters, 2011, Volume: 32, Issue:5

    Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperidol; Humans; Male; Medical Records; Olanzapine; Perphenazine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome

2011
Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study.
    Psychiatric services (Washington, D.C.), 2013, Volume: 64, Issue:6

    Topics: Adult; Antipsychotic Agents; Black or African American; Clinical Trials as Topic; Female; Hispanic or Latino; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Dropouts; Perphenazine; Piperazines; Schizophrenia; Thiazoles; United States; White People; Young Adult

2013